Grufity logoGrufity logo
StocksFundsSearch Filings

Beam Therapeutics Inc. Stock Research

BEAM

32.37USD+0.16(+0.50%)Market Closed

Market Summary

USD32.37+0.16
Market Closed
0.50%

BEAM Alerts

BEAM Stock Price

BEAM RSI Chart

BEAM Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-7.62

Price/Sales (Trailing)

31.42

EV/EBITDA

-8.8

Price/Free Cashflow

-6.82

BEAM Price/Sales (Trailing)

BEAM Profitability

EBT Margin

-427.08%

Return on Equity

-39.41%

Return on Assets

-21.55%

Free Cashflow Yield

-14.67%

BEAM Fundamentals

BEAM Revenue

Revenue (TTM)

76.7M

Revenue Y/Y

187.1%

Revenue Q/Q

20.82%

BEAM Earnings

Earnings (TTM)

-316.3M

Earnings Y/Y

-39.36%

Earnings Q/Q

-151.53%

Price Action

52 Week Range

28.0473.27
(Low)(High)

Last 7 days

-6.3%

Last 30 days

6.0%

Last 90 days

-16.8%

Trailing 12 Months

-0.6%

BEAM Financial Health

Current Ratio

4.89

BEAM Investor Care

Shares Dilution (1Y)

6.71%

Diluted EPS (TTM)

-4.45

Peers (Alternatives to Beam Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
115.9B
26.2B
-9.16% -12.25%
14.64
4.43
-0.48% 38.34%
96.2B
27.0B
-7.94% 24.63%
17.23
3.56
-1.56% 23.65%
48.5B
15.1B
-3.43% -7.04%
10.13
3.22
-33.37% -67.32%
43.1B
10.1B
3.69% 46.24%
13.77
4.27
-6.61% 115.98%
MID-CAP
8.9B
1.6B
-11.20% 1.54%
138.97
5.56
32.38% -10.36%
4.1B
-
22.94% 24.01%
-11.06
37.77
122.90% -29.67%
2.4B
76.7M
5.96% -0.58%
-7.62
31.42
41.73% -32.75%
2.2B
107.9M
-3.78% 107.70%
-4.55
20.44
54.84% 17.36%
SMALL-CAP
1.6B
119.0M
22.46% 21.04%
-5.77
13.53
-69.61% -584.39%
1.1B
10.0M
16.71% 38.03%
-6.34
110.4
215.65% -47.65%
622.2M
-
-4.25% -84.68%
-0.54
0.31
72.89% 12.32%
503.7M
136.9M
-11.86% -77.13%
-2.14
3.68
116.83% -0.93%
210.2M
241.0M
-21.74% -64.41%
-1.65
0.87
113.96% 27.87%
162.7M
697.0K
67.22% -64.71%
-1.51
233.45
47.98% -35.48%
9.3M
-
-31.01% -87.63%
-0.12
3.21
0.51% -129.47%

Financials for Beam Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue25.9%76,696,00060,920,00058,651,00056,382,00054,113,000
Operating Expenses9.6%437,878,000399,399,000404,930,000368,225,000328,587,000
  S&GA Expenses4.8%92,048,00087,805,00082,896,00076,855,00066,196,000
  R&D Expenses11.0%345,830,000311,594,000322,034,000291,370,000262,391,000
EBITDA12.1%-245,655,000-279,483,000---
EBITDA Margin15.4%-4.03-4.77---
Earnings Before Taxes11.1%-260,178,000-292,744,000---
EBT Margin14.4%-4.27-4.99---
Interest Expenses-13.6%325,000376,000424,000474,000521,000
Net Income-9.4%-316,334,000-289,088,000-315,446,000-233,989,000-238,292,000
Net Income Margin11.8%-4.75-5.38-4.51--
Free Cahsflow-166.9%-26,424,00039,489,000122,999,000148,208,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-0.7%1,3321,3421,3501,4181,453
  Current Assets-0.9%1,0831,0931,1091,1801,239
    Cash Equivalents11.5%260233157266297
  Net PPE5.4%12211611110694.00
Liabilities-6.1%571608636618624
  Current Liabilities-1.6%220224239212219
Shareholder's Equity3.8%762733714800829
  Retained Earnings-4.9%-1,153-1,100-1,000-909-837
  Additional Paid-In Capital6.9%1,9151,7931,7371,7131,669
Accumulated Depreciation15.3%26.0023.0019.00--
Shares Outstanding4.4%74.0071.0070.0070.0070.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-1457.4%-30523.0094.00171191
  Share Based Compensation7.0%90.0084.0077.0068.0057.00
Cashflow From Investing122.0%101-461-652-539-551
Cashflow From Financing38.3%154112101420559

Risks for BEAM

What is the probability of a big loss on BEAM?

66.5%


Probability that Beam Therapeutics stock will be more than 20% underwater in next one year

66.5%


Probability that Beam Therapeutics stock will be more than 30% underwater in next one year.

50.8%


Probability that Beam Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BEAM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Beam Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for BEAM

Cumulative Returns on BEAM

-7.0%


10-Year Cumulative Returns

10%


3-Year Cumulative Returns

What are the long-term rolling returns for BEAM?

FIve years rolling returns for Beam Therapeutics.

Annualized Returns

Which funds bought or sold BEAM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Capital Impact Advisors, LLC
added
3.66
-89,570
385,812
0.47%
2023-05-22
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO
new
-
1,832,000
1,832,000
0.70%
2023-05-22
AMERIPRISE FINANCIAL INC
sold off
-100
-287,000
-
-%
2023-05-18
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
unchanged
-
-201,160
717,925
0.20%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-18.62
-786,000
1,381,000
-%
2023-05-18
JPMORGAN CHASE & CO
reduced
-2.6
-6,884,690
22,111,300
-%
2023-05-17
Advisory Services Network, LLC
unchanged
-
-1,103
3,981
-%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-34.12
-185,924
219,016
-%
2023-05-16
Ancora Advisors, LLC
unchanged
-
-469
1,531
-%
2023-05-16
CHILTON CAPITAL MANAGEMENT LLC
new
-
3,828
3,828
-%

1–10 of 41

Latest Funds Activity

Are funds buying BEAM calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BEAM
No. of Funds

Beam Therapeutics News

Best Stocks
UBS Group AG Increases Shares in Beam Therapeutics Inc. by ....
Best Stocks,
8 hours ago
Stockhouse Publishing

Schedule 13G FIlings of Beam Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 17, 2023
temasek holdings (private) ltd
5.0%
3,644,573
SC 13G
Feb 14, 2023
farallon capital partners, l.p.
0.0%
0
SC 13G/A
Feb 10, 2023
temasek holdings (private) ltd
4.1%
2,878,297
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.90%
6,273,630
SC 13G/A
Feb 02, 2023
blackrock inc.
7.4%
5,238,280
SC 13G/A
Jul 14, 2022
farallon capital partners, l.p.
0.4%
276,948
SC 13G
Feb 14, 2022
arch venture fund ix, l.p.
8.6%
5,843,039
SC 13G/A
Feb 14, 2022
redmile group, llc
2.8%
1,885,850
SC 13G/A
Feb 14, 2022
temasek holdings (private) ltd
5.8%
3,959,212
SC 13G/A

BEAM Fair Value

Recent SEC filings of Beam Therapeutics

View All Filings
Date Filed Form Type Document
May 10, 2023
10-Q
Quarterly Report
May 10, 2023
424B5
Prospectus Filed
May 10, 2023
8-K
Current Report
May 10, 2023
8-K
Current Report
Apr 21, 2023
ARS
ARS
Apr 21, 2023
DEF 14A
DEF 14A
Apr 21, 2023
DEFA14A
DEFA14A
Apr 19, 2023
4/A
Insider Trading
Apr 05, 2023
4
Insider Trading
Apr 05, 2023
4
Insider Trading

Latest Insider Trading transactions for BEAM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-04-04
Simon Amy
sold
-346,115
29.6993
-11,654
chief medical officer
2023-04-04
Evans John M.
sold
-188,904
29.0935
-6,493
ceo
2023-04-04
Bellon Christine
sold
-33,777
29.0931
-1,161
chief legal officer
2023-04-04
Burrell Terry-Ann
sold
-63,597
29.0931
-2,186
chief financial officer
2023-04-04
Ciaramella Giuseppe
sold
-51,028
29.0929
-1,754
president & cso
2023-04-03
Simon Amy
sold
-134,728
30.31
-4,445
chief medical officer
2023-04-03
Ciaramella Giuseppe
sold
-58,134
30.31
-1,918
president & cso
2023-04-03
Burrell Terry-Ann
sold
-74,380
30.31
-2,454
chief financial officer
2023-04-03
Bellon Christine
sold
-28,218
30.31
-931
chief legal officer
2023-04-03
Evans John M.
sold
-156,430
30.31
-5,161
ceo

1–10 of 50

John Evans
340
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Income Statement

2023-03-31
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
License and collaboration revenue$ 24,208$ 8,432
Revenue, Product and Service [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:  
Research and development$ 99,646$ 65,410
General and administrative23,49019,247
Total operating expenses123,13684,657
Loss from operations(98,928)(76,225)
Other income (expense):  
Change in fair value of derivative liabilities5,60013,600
Change in fair value of non-controlling equity investments(12,797)(7,685)
Change in fair value of contingent consideration liabilities(296)452
Interest and other income (expense), net9,961644
Total other income (expense)2,4687,011
Net loss(96,460)(69,214)
Unrealized gain (loss) on marketable securities1,665(2,659)
Comprehensive loss$ (94,795)$ (71,873)
Net loss per common share, basic$ (1.33)$ (1.01)
Net loss per common share, diluted$ (1.33)$ (1.01)
Weighted - average common shares outstanding, basic72,273,82968,703,864
Weighted - average common shares outstanding, diluted72,273,82968,703,864

BEAM Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 249,771$ 232,767
Marketable securities809,700845,367
Prepaid expenses and other current assets23,56014,762
Total current assets1,083,0311,092,896
Property and equipment, net121,822115,620
Restricted cash9,80212,754
Operating lease right-of-use assets116,159118,513
Other assets1,5381,931
Total assets1,332,3521,341,714
Current liabilities:  
Accounts payable14,0639,029
Accrued expenses and other current liabilities37,84748,059
Derivative liabilities12,70018,300
Current portion of deferred revenue142,737135,974
Current portion of lease liability11,15710,380
Current portion of equipment financing liability1,4211,853
Total current liabilities219,925223,595
Long-term lease liability165,298168,625
Long-term equipment financing liability9831,154
Contingent consideration liabilities12,75912,463
Long-term portion of deferred revenue171,708202,179
Other liabilities173224
Total liabilities570,846608,240
Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements)
Stockholders’ equity:  
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2023 and December 31, 2022 , respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 74,435,392 and 71,277,339 issued and outstanding at March 31,2023 and December 31, 2022 respectively744712
Additional paid-in capital1,915,3491,792,554
Accumulated other comprehensive (loss) income(765)(2,430)
Accumulated deficit(1,153,822)(1,057,362)
Total stockholders' equity761,506733,474
Total liabilities and stockholders' equity$ 1,332,352$ 1,341,714